Quick Answer
Actinium Pharmaceuticals, Inc. reported Total Revenue of $90.0 thousand for the year ending 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +11.1% in Total Revenue from 2023 to 2025.
- This data is from Actinium Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $622.0 thousand | Q2 2021: $266.0 thousand | Q3 2021: $233.0 thousand | Q1 2022: $940.0 thousand | Q2 2022: $45.0 thousand | Q3 2022: $45.0 thousand | Q3 2025: $90.0 thousand.
- Over the full 4 years of available data (2021 to 2025), Actinium Pharmaceuticals, Inc.'s Total Revenue has declined by 92.1%.
- Historical annual values: Fiscal year 2025: $90.0 thousand | Fiscal year 2023: $81.0 thousand | Fiscal year 2022: $1.03 million | Fiscal year 2021: $1.14 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: